A male in his 50s presented with profound leucocytosis, systemic symptoms and marked hepatosplenomegaly. Initial workup with peripheral blood flow cytometry suggested T-cell prolymphocytic leukaemia as the most likely diagnosis. However, bone marrow biopsy with comprehensive immunogenetic testing ultimately identified anaplastic lymphoma kinase-positive anaplastic large cell lymphoma in its leukemic phase. The treatment course was with targeted agents with less immunosuppressive risk, after taking into consideration that he was a Jehovah’s Witness, who would not be able to receive blood products. Despite a transient response, the disease progressed rapidly. This case underscores the importance of a broad differential diagnosis, judicious use of advanced diagnostics and individualised treatment planning, particularly in rare and aggressive lymphoproliferative disorders.
We present a case of a patient in her 70s with an 11-month history of Rai stage 1 chronic lymphocytic leukaemia (CLL) who presented to the emergency department with bilateral lower extremity weakness, frequent falls, urinary retention and incontinence worsening for 2 weeks. Whole-spine MRI with and without contrast revealed continuous patchy and confluent enhancement from C1–T10, consistent with lymphomatous infiltration. Lumbar puncture with flow cytometry demonstrated cerebrospinal fluid involvement of CLL. She started on zanubrutinib with an excellent clinical response. Follow-up whole-spine MRI after 12 weeks of therapy revealed resolution of prior areas of abnormal enhancement. Central nervous system (CNS) involvement in CLL is rare and can cause debilitating symptoms. New neurologic symptoms in patients with a known CLL history should prompt investigation to assess for transformation and CNS involvement. Treatment with a Bruton tyrosine kinase inhibitor such as zanubrutinib or a venetoclax-based regimen may be necessary.
Immune checkpoint inhibitors and other targeted therapies have substantially improved outcomes for patients with advanced melanoma; however, effective treatment options remain limited following treatment resistance. Poly(ADP-ribose) polymerase (PARP) inhibitors are an established therapeutic strategy in several malignancies with defects in homologous recombination repair, and emerging evidence suggests a potential role for PARP inhibition in melanoma. Alterations in homologous recombination repair and other DNA damage response pathways occur in a subset of melanomas and may create therapeutic vulnerabilities to PARP inhibition. In addition to their direct effects on DNA repair, PARP inhibitors have immunomodulatory properties that provide a biologic rationale for combination with immune checkpoint blockade. Preclinical melanoma models have demonstrated activity of PARP inhibition alone and in combination with chemotherapy, while early clinical studies have shown preliminary activity in selected patients with advanced melanoma. However, the presence of a homologous recombination repair/DNA damage response gene alteration does not necessarily indicate functional homologous recombination deficiency or predict sensitivity to PARP inhibition. This review examines the biologic rationale, preclinical and clinical evidence, and emerging combination strategies for PARP inhibition in melanoma, with particular emphasis on the challenges of biomarker selection and priorities for future clinical investigation.